SAN FRANCISCO - Jaguar Health, Inc. (NASDAQ:JAGX), a commercial stage pharmaceuticals company, announced the appointment of Catherine Miller Collis as Senior Vice President of Growth Strategy. Collis, who played a pivotal role in the recent in-licensing of Gelclair®, is a seasoned professional with over two decades of experience in the biopharmaceutical sector.
Lisa Conte, Jaguar's president and CEO, expressed confidence in Collis's abilities, citing her extensive background in commercial and business development. Collis's expertise is expected to be crucial as the company advances its growth strategy, particularly in cancer and gastrointestinal (GI) supportive care.
The company is preparing for the commercial launch of Gelclair, a protective gel for oral mucositis management—a common side effect of cancer treatments.
Collis shared her enthusiasm for joining Jaguar and contributing to the company's portfolio of FDA-approved prescription products. She highlighted the importance of providing cancer patients with supportive care products that offer soothing pain relief without numbing, emphasizing safety and effectiveness.
Jaguar Health is expanding its focus to include cancer-related supportive care, with Gelclair being a foundational element in this strategy. The company also awaits results from its pivotal Phase 3 OnTarget trial of crofelemer for chemotherapy-induced overactive bowel (CIOB).
Prior to joining Jaguar, Collis held various leadership roles in companies like Vibrant Gastro, Ironwood Pharmaceuticals, and Zealand Pharma (NASDAQ:ZEAL), where she was involved in developing and commercializing therapies for GI disorders and diseases.
She has a proven track record in creating and executing innovative commercial strategies and has been instrumental in launching multiple blockbuster brands across different regions and therapeutic areas.
Gelclair is indicated for the management of pain and relief of pain in conditions such as oral mucositis/stomatitis, which may be caused by chemotherapy or radiation therapy, and other oral lesions. The safety information for Gelclair advises against its use in cases of known hypersensitivity to its ingredients, and no adverse effects are anticipated if swallowed accidentally.
This news is based on a press release statement from Jaguar Health, Inc.
InvestingPro Insights
In light of Jaguar Health, Inc.'s recent strategic appointment and their focus on expanding into cancer-related supportive care, current and potential investors may be keen to understand the company's financial health and stock performance. According to InvestingPro data, Jaguar Health has a market capitalization of $45.55 million, indicating its size within the pharmaceuticals market.
Despite the company's endeavors in product development and commercialization, analysts from InvestingPro have noted that the company has not been profitable over the last twelve months, with a significant adjusted operating income loss of approximately $33.92 million.
Investors should also note the company's high price volatility, as highlighted by the InvestingPro Tips. This could be attributed to recent developments and market reactions to the company's strategic moves.
Moreover, the stock has seen a substantial return over the last month, with a price total return of 137.61%, showcasing a period of strong performance. Still, the long-term view presents a different picture, with the price having fallen significantly over the last year by 72.92%.
For those considering a deeper dive into Jaguar Health's financials and stock performance, InvestingPro offers a range of additional tips—there are 12 more InvestingPro Tips available for JAGX, which can provide further insights into the company's valuation and market expectations. For investors looking to take advantage of these insights, remember to use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.